Setanaxib clinical trials
Also written GKT137831.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses setanaxib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Calliditas Therapeutics AB (5) · Calliditas Therapeutics Suisse SA (2) · University of Alabama at Birmingham (1)
Studies
Open first, then newest update. How each study uses setanaxib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisCompletedPhase 2University of Alabama at BirminghamNCT03865927Written as GKT137831
- A Study to Evaluate Setanaxib in Patients With Alport SyndromeCompletedPhase 1/2Calliditas Therapeutics ABNCT06274489Written as Setanaxib
- A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedPhase 2Calliditas Therapeutics Suisse SANCT05323656Written as Setanaxib
- A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver StiffnessCompletedPhase 2Calliditas Therapeutics Suisse SANCT05014672Written as Setanaxib
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and AlbuminuriaCompletedPhase 2Calliditas Therapeutics ABNCT02010242Written as GKT137831
- Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female SubjectsCompletedPhase 1Calliditas Therapeutics ABNCT04327089Written as Setanaxib
- Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in TabletsCompletedPhase 1Calliditas Therapeutics ABNCT03740217Written as GKT137831
- Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.CompletedPhase 2Calliditas Therapeutics ABNCT03226067Written as GKT137831
Codes
What other systems call setanaxib · ClinicalTrials.gg INT006189
- MeSH (NLM) C576694setanaxibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 45II35329VSETANAXIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27258840setanaxibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166721SetanaxibOne source FDA
- DrugBank DB16869One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C576694 | setanaxib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 45II35329V | SETANAXIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27258840 | setanaxib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166721 | Setanaxib | One source FDA |
| DrugBank | DB16869 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.